Zacks.com on MSN19h
FDA Accepts GSK's BLA for Blenrep Combos in Multiple Myeloma
The FDA accepts GSK's BLA seeking approval of Blenrep combinations for treating relapsed/refractory multiple myeloma. A decision is due on July 23, 2025.
FiercePharma12d
GSK's ADC Blenrep delivers survival win against J&J's Darzalex
GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...
GSK's Blenrep treatment accepted for review by FDA
Pharma titan GSK has announced that US regulators have accepted for review Blenrep combinations for the treatment of relapsed ...
Cure Today8d
Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma
Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be ...
GlobalData on MSN1d
GSK eyes up combo approval for previously withdrawn myeloma drug
The US Food and Drug Administration (FDA) is expected to make a Prescription Drug User Fee Act (PDUFA) decision by mid-2025.
Daily1d
USFDA accepts for review application for GSK Blenrep combinations for multiple myeloma treatment
London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License ...
GSK :FDA Accepts Blenrep Combination For Review In Treatment Of Relapsed/Refractory Multiple Myeloma
GSK plc (GSK, GSK.L) announced that the US Food and Drug Administration has accepted for review a Biologics License Application (BLA) ...
GSK’s Blenrep Nears FDA Review for Myeloma
GlaxoSmithKline (GB:GSK) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now ...
BioSpace12d
GSK Builds Case for Blenrep with Multiple Myeloma OS Data That Bests J&J’s Darzalex
GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...
Benzinga.com12d
GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market - Here's Why
The DREAMM-7 trial showed Blenrep with BorDex lowered death risk in relapsed/refractory multiple myeloma vs. standard ...
The Pharma Letter11d
Blenrep results ‘transformative’, GSK says
UK drugmaker GSK might be trading lower following Thursday’s nomination of vaccine sceptic Robert F Kennedy Jr as the USA’s ...
Pharmabiz1d
US FDA accepts for review GSK’s Blenrep combinations for the treatment of relapsed/refractory multiple myeloma
US FDA accepts for review GSK’s Blenrep combinations for the treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, November 26, 2024, 09:00 Hrs [IST] GSK plc an ...